#6-04E. Navigating Biologic Safety in Pregnant Psoriasis Patients: Evidence and Clinical Practice (Pharmaceuticals, 2026)

How do clinicians balance effective maternal disease control and fetal safety when managing pregnant women with plaque psoriasis who require biologic therapy? Analyzing 290 pregnancies across 11 studies, this review demonstrates that biologic exposure is generally associated with favorable maternal and fetal outcomes comparable to general population rates—with certolizumab pegol showing the highest safety profile due to minimal placental transfer—though findings remain constrained by a reliance on small observational cohorts susceptible to reporting bias. Ultimately, this evidence supports prioritizing maternal disease control through shared, individualized decision-making rather than routinely discontinuing essential biologic treatment during pregnancy.

Citation: Nagendra S, Karampinis E. Biologic Therapy in Pregnant Women with Plaque Psoriasis: A Narrative Review of Maternal and Fetal Safety Considerations. Pharmaceuticals. 2026.

DOI: 10.3390/pharmaceuticals2026

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.